Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

PEGPH20 Offers New Mechanism for Attacking Pancreas Tumors

September 29th 2017

PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.

Lead FLAURA Researcher Discusses Frontline Osimertinib in EGFR+ NSCLC

September 29th 2017

Suresh A. Ramalingam, MD, discusses the practice-changing FLAURA findings and his thoughts on sequencing should the FDA approve osimertinib in the frontline setting of non-small cell lung cancer.

Future Directions in NSCLC Immuno-Oncology Research

September 28th 2017

Immuno-Oncology Combination Therapy in NSCLC

September 28th 2017

Promising Immunotherapy Agents for NSCLC

September 28th 2017

PACIFIC Trial: Durvalumab for Stage 3 NSCLC

September 28th 2017

Immunotherapy for Management of Stage 3B NSCLC

September 28th 2017

Immunotherapy Toxicity Management in NSCLC

September 28th 2017

Treatment for NSCLC After Progression on Immunotherapy

September 28th 2017

Combination Approaches for Second-Line Therapy for NSCLC

September 28th 2017

The Role of Mutation Burden as a Biomarker in NSCLC

September 28th 2017

Immunotherapy for Relapsed or Refractory NSCLC

September 28th 2017

Isolated Progression of NSCLC on Immunotherapy

September 28th 2017

The Potential for IO Use as Maintenance Therapy in NSCLC

September 28th 2017

Duration of Upfront Immunotherapy for NSCLC

September 28th 2017

Patient Selection for Upfront Immunotherapy in NSCLC

September 28th 2017

Upfront PD-L1 Blockade in Newly Diagnosed NSCLC

September 28th 2017

NSCLC Immunotherapy: Transformation of Upfront Therapy

September 28th 2017

Bladder Cancer Paradigm Expanding to Include Immunotherapy Combos, Targeted Therapies

September 28th 2017

Terence Friedlander, MD, discusses the targeted therapies emerging in the field of bladder cancer, as well as immunotherapy combinations that are traveling through the pipeline.

Dr. Armstrong on Precision Medicine for Metastatic Prostate Cancer

September 26th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses precision medicine for patients with metastatic prostate cancer.